Precision medicine, drug discovery and cell/gene therapies are driving adoption, creating opportunities in automation, spatial multi-omics, AI bioinformatics and clinical diagnostics.Dublin, Sept. 24, ...
In adult neuroendocrine malignancies, including small cell lung cancer, Delta-like ligand 3 (DLL3) is a validated therapeutic target. DLL3 is expressed in neuroblastoma, a pediatric cancer of ...
Translational Pathology provides high-plex immunohistochemistry staining (PhenoCycler, aka CODEX), IHC-related image analysis, and expertise services and support in both collaborative and ...
Labroots is pleased to announce the 5th annual event in the Immuno-Oncology Virtual Event Series taking place on April 29th, 2026. Immuno-Oncology is at the forefront of groundbreaking research in ...
There are two key things to know about the new Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer from Thermo Fisher Scientific, said Ravi Gupta, vice president and general manager of Thermo ...
The Conference Forum today announced the launch of the 12th annual Immuno-Oncology 360º Summit (IO360°) taking place February 10-12, 2026, at the Sheraton Boston Hotel in Boston, MA. “IO360º provides ...
ATLANTA, GA - July 28, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunotherapies against infectious ...
ABSTRACT: Primary neuroendocrine carcinoma of the male breast is an exceptionally rare entity, with fewer than 50 cases documented in the literature. We present a case of a 71-year-old male with a ...
The following is a summary of “GPX4 expression changes in proximal tubule cells highlight the role of ferroptosis in IgAN,” published in the January 2025 issue of Scientific Reports by Qing et al.
Abstract: The purpose of this document is to introduce the application of manual tissue microarrays in the production of immunohistochemistry (IHC) positive tissue controls for ALK, P16, HER2, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results